A Novel Synthetic Vitamin A-like Compound (A Polyprenoic Acid Derivative, E-5166) Inhibits the Release of Arachidonic Acid Stimulated by Epidermal Growth Factor  by Suya, Hideko et al.
A Novel Synthetic Vitamin A-like Compound 
(A Polyprenoic Acid Derivative, E-5166) Inhibits the 
Release of Arachidonic Acid Stimulated by 
Epidermal Growth Factor 
Hideko Suya, B.Sc.,* Takashi Aoyagi, M.D., Hiroko Koizumi, M.D., Toru Fukaya, M.D., and 
Osamu Nemoto, M.D. 
Department of Dermatology, Hokkaido University School of Medicine, Sapporo, Japan 
Little is known about the mechanisms of anti-inflammatory 
activity of retinoids. A new synthetic vitamin A-like com-
pound (polyprenoic acid derivative, E-5166) has a strong 
in vitro binding affinity to intracellular binding proteins 
for acidic retinoids . In order to elucidate the anti-inflam-
matory activity ofE-5166, we studied the effect ofE-5166 
on the epidermal growth factor (EGF)-stimulated arachi-
donic acid (A A) release of pig epidermis . E-5166 signifi-
V itamin A and its synthetic analogs (retinoids) have been shown to control cellular differentiation and proliferation in many tissues [1]. Besides the inhi-bition of cell proliferation, the effects of retinoids in cystic acne and psoriasis have been attributed to their 
anti-inflammatory action [2,3]. It has been postulated that the 
anti-inflammatory ac tivity might be due to inhibition of the pro-
duction of arachidonic acid (AA)-derived mediators of inflam-
mation, but there are few reports dealing with the abi lity of 
retinoids to inhibit AA metabolism [4]. 
A new synthetic vitamin A-like compound (3,7,11, 15-tetra-
methyl-2,4,6, 10, 14-hexadecapentaenoic acid, E-5166), which was 
originally described by Muto et al [5,6], had a strong in vitro 
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Abbreviations: 
AA: arachidonic acid 
A23187: ionophore A23187 
BSA: bovine serum albumin 
DG: diglycero l 
EGF: epidermal growth factor 
E-5156: 3,7, 11, 15-tetrameth yl-2,4,6, 1 0, 14-hexadecapentaenoic acid 
HC: hydrocortisone 
KRB : Krebs-Ringer buffer 




PLase A2: phospholipase A2 
PS: phosphatidylserine 
TPA: 12-0-tetradecanoylphorbol-13-acetate 
can dy inhibited the EGF-stimulated AA release and this 
inhibitory effect of E-5166 required a longer incubation 
than hydrocortisone did . Furthermore, E-5166 inhibited 
the EGF-stimulated phosphatidylinositol (PI) turnover of 
pig epidermis. These results indicate that E-5166 inhibited 
the EGF-stimulated AA release through the inhibition of 
the EGF-stimulated PI turnover. J Invest Dermatol 88:630-
633, 1987 
binding affinity to intracellular binding proteins for acidic reti-
noids. In order to elucidate the anti-inflammatory action of E-
5166, we studied the effect of E-51 66 ·on the AA metabolism 
particularly the phospholipid-breakdown sys tem of pig epider~ 
mis. As we have already reported that epidermal growth factor 
(EGF) and other phospholipase Az (PLase A z) stimulators in-
creased the AA release from membrane phospholipids of pig ep-
idermis [7], we studied the effect ofE-5166 on the EGF-stimulated 
AA release of pig epidermis. 
In this paper, we report that E-5166 significa ntly inhibited the 
EGF-stimulated AA release and this inhibitory effect of E-5166 
required a longer incubation than HC did. Furthermore, we dis-
cuss different mechanisms of action of E-5166 and HC on the 
inhibition of the AA release in pig epidermis . 
MATERIALS AND METHODS 
Skin sli ces were taken from the backs of domestic pigs, weighing 
6-8 kg, by a Castro viejo keratome set at 0.2 mm depth. As skin 
slices thus obtained contain mainly epidermis (80-90% ), they are 
called epidermal slices [8]. During procedure, pigs were anesthe-
tized with Nembutal (20-30 mg/kg) i. p. Epidermal slices kept in 
RPMI 1640 medium at 4°C were then cut into 5 X 10 mm and 
used within 30 min. 
Epidermal slices were pretreated with or without E-5166 or 
hydrocorti sone (HC) for indicated periods, and then prelabeled 
with [J-I 4CJarachidonic acid W'CJAA) (0 .1 /LCi/ml) for 4 h in 
RPMI 1640 medium with 2% bovine serum albumin (BSA) at 
37°C in a high-humidity incubator in a mixture of 5% COz in 
alL 
After prclabeling, ep idermal slices were washed twice in Ca + + _ 
free RPMI 1640 med ium with 1 mM ethyleneglycoltetraacetic 
acid , and then incubated with or without EGF or other test drugs 
in Ca + + -free RPMI 1640 with 1.2 mM Ca;- + and 2% BSA at 
37°C for 20 min . The incubation was term.inated by removing 
samples from the medium immediately. The radioactivity of 
['4C]AA released in the medium was determined as previously 
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described 17 1. In this ex periment sys tcm , we did no t detect any 
sign ifica nt di ffe rencc of I.IC -labcled AA meta bo lites rcieascd in 
the rTIed ium betwcen contro l and E-5 166 t lTat ment. T he AA 
con te n t in the med iulll w as m o re tlu n 85% of th e to tal ac ti vit y. 
Fo r t he stud y of phos pho li pid brea kdown, epiderm al sli ces 
pretreated w ith o r w ith out E- 5 166 fo r 22 h were preiabci ed w ith 
[3H ]g lycero l (2 JLC i/ ml ) fo r J h and then in cubated w ith o r w ith-
o u t EGF fo r indi ca ted perio ds. T he in cubation med iul11 was the 
mod ified Krebs-r~ in ge r buffe r (10 m) w ith HE I'ES (20 m M, pH 
7.4) in t he prese nce of l. 2 m M Ca+ +. T he sa mpl es were rinsed 
in a c hil led KRB and immediatciy frozen between 2 dry- icc pl ates 
to te rrnin ate the reacti on. 
T h e sa mples were thm ho m ogeni zed w ith a g la ss ho m ogenize r 
in 3 ml of chl o ro fo rm :meth ano l (2 :1 ) o r methano l at 4°C. After 
homogeni zat ion , I ml of 2 M KC I. so lutio n was added and the 
uppe r p hase was rcm ovcd . The ex tract was eva po rated to a small 
volum e w ith ni t rogen gas. Lipids and phospho lipids labeled w ith 
[3H ]g l ycero l w ere dissolved in chl o rofor m and analyzcd by thin-
laye r c hro m atog raph y (precoa ted Sili ca Gci G Pl atc, Wako C hem-
ica ls, Osaka , j apan) as described by Sn yder 19 1. The so lvcnt sys-
tem con ta in cd chl o rofo rm: methano b ceti c ac id :H 20 (50 :25 :8:4) 
for p h os pho li pids and li g rain c:eth ano b ceti c acid (50:50: 1) fo r lip-
ids . Each spo t o f lipids and phospho lipids was scraped and its 
rad ioact ivity was de termin ed b y a scin till ati o n co unter . 
For t h e study of IJHlinosito l in co rporati on into phos phati-
dyli nos i tol (PI ), a lo ng in cubatio n sys tcm was empl oyed . E pi-
dermal s li ces pretrea ted w ith o r w itho ut E-5166 fo r 22 h were 
washed tw ice and then in cubated w ith o r w itho ut EG F in the 
prese n ce of rJH li nosito l ( I JLC i/ ml) fo r '1 h. T he in cubatio n m e-
diu m was KR.B w ith H E PES (20 111 M, pH 7.4) in the prescnce 
of Ca -I- + (1.2 m M) . The sa mp les were ho m ogenized and phos-
pholipid frac ti on was extracted . The radioacti vity of an aliq uot 
of p h ospho li pid fractio n labeled w ith IJHlinos ito l was determin ed 
by a scintillation counter as described prev iously [1 01. 
Prote in content was meas ured by the m eth od of Low ry et al 
[11 ]. 
T h e fo llowin g chemi ca ls and drugs we re o btain ed fro lll the 
indica t ed so urces: IJH Ig lycero l, 13H]in os ito l, and 114C] AA (Amer-
sham J a pan , Tokyo, j apan); EG F (Co llaborati ve Resea rch Inc., 
Wa ltb arn , Massac hu setts); lo no pho re A23 187 (A23 187) (Ca lbi-
och e m-Behrin ger Co., Sa n D iego, Ca li fo rn ia); H C, 12- 0 - tetra-
deca n oy lpho lbol-1 3- ace tate (TP A), phos phatid ylethano lamin e 
(PE) , ph osphatidylcho li ne (PC), phosphatid ylserine (PS), and .BSA 
(essen tia l fa tty acid-free) (S ig m a C hel1lical Co. , St. Louis, Mis-
souri); a n d RPMI1 640 and Ca +l -ti'ee RPM I1 640 med ia (G I.B CO, 
Gra n d l shnd , N ew Yo rk). E- 51 66 was a generolls g ift o f Eisa i 
Co., L t d . , Tokyo, j J pan . All other chemi cals and dru gs were 
analy ti c reagcnt g rade. 
RES ULTS 
As sh own in Ta ble I, E-5 '166 at "100 JL M had no detectabl e effect 
on th e A A release stimulated by either A23187, EG F, o r TPA , 
Table I. Effect ofE- 5 :1 66 o n the AA Helcase Stimulated by 
A23187, EG F, and T PA 
None 
A23187 ( 10 /LM) 
EG F (0 .1 /L g/ ml) 
TPA (1 /-LM) 
Tota l in corpo rat ion 
AA Hcleasc (dpm / m g pro tcin / 20 min) 
Contro l 
175 :t 12.9 
500 ± 34.7 
243 ± 1. 1 
277 ± 5.0 
4,250 ± 174.0 
E-5 166 (100 /LM) 
160 ± 2.7 
455 ± 50. 1 
244 ± 2.6 
254 ± 3.6 
4,29 1 ± 37.3 
Epidermal s lices prcl abcled w ith I "ClAA (0. 1 /LC i/ llIl ) we re in cub ated wi th o r 
wi thout E-5 166 ( 100 /L M) in ,he presence o r absence o{ A23 187 (10 /L M). EGF (0. 1 
/Lg/m l). o r T I' A ( I /L M) {or 20 min . T he a mo unt o q " C IAA released in the m edium 
was d e termined and expressed as dp m / m g pro tein ± SEM. N umber of sa 'np lcs = 
3. T o ta l in co rporatioll of 11-1C IA A illto cp id cr l1l :d slices \V:lS dctc rlllill t.'d and ex-
pressed 3 S dpm / m g protein ± SEM . 
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Table II. E ffect of E-51 66 on the AA Helease Stimul ated by 
A23187, EG F, and T PA 
AA Release (d pm/ mg protein/20 m in) 
N onc 
A23 187 (10 /LM) 
EG F (0. 1 /Lg/ ml ) 
T I'A ( I/LM) 
Tota l incorpo rat ion 
Contro l 
255 ± 25.0 
682 ± 7 1. 8 
455 ± 30.4 
486 ± 49.4 
5,284 ± 425 
E-5166 (100 /LM) 
199 ± 18.6 
460 ± 74.8 
236 ± 3 1. 7" 
303 ± 3 1 (i' 
5.077 ± 343 
Epider m al sli ces p rcl abek d w ith o r wi tho ut E-5 166 (100 /LM) {o r 22 hr were 
in cubated w ith I"ClAA (0. 1 /LC i/ ml), and then incu ba ted w ith o r w itho ut A23 187 
( IC) /L M). EGF (0 . 1 /Lg/ ml). and T I' A ( I /L M) for 20 m in . T he am o unt of I "ClAA 
rck ascd ill rh e med iulli WJS de termi ned :l1ld exp ressed as dpm / lll g protcill / 20 mi n 
± SEM . Total in co rpora tion of I "ClAA into epider m al s lices was d ete n ni ned and 
e'p rcssed as dp m / m g protein ± SEM . N um ber of sa 111 pies = 6. 
"1' < 0.0 1 (co m pared w ith contro l). 
1,1' < 0.025 (CO llI pared w ith contro l). 
w hen it was simu ltaneously added to the incubation m edium w ith 
PLase A2 stimula to rs . 
When epidermal sli ces were pretrea ted w ith E-5166 at 100 JL M 
fo r 22 h , it signifi cantly inhibited the AA release stimulated by 
EGF as shown in Ta ble II. The T PA-stimulated AA release was 
also inhibited by th e pretrea tm ent w ith E-5166, but the A23 187-
stimulated one was no t. A prelabelin g fo r 4 h w ith [ '4C] AA 
resu lted in almost the sa m e am ount of I.IC incorporation in to to tal 
phospho lipids o f the control o r E-5166-treated epiderm al sli ces. 
As sho wn in Fig I , E-5166 required at leas t 6 h to inhibit th e 
EG F-st imulated AA release. E-5166 at 100 JLM induced 60% in-
hibition o f the EG F-stil11ulated AA release b y 22-h pretrea tm ent. 
Fi gure 2 shows a dose-dependent stud y of E-5166 effect. E-
5166 at less than 10 JLM had no effect, but 100 JL M and 1 111 M of 
E-5 166 inhibited the EG F-stimulated AA release . 
As shown in Fig 3, the addition of cycloheximide at 1 JLg/ml , 
an inhibi to r of pro tein synthesis, partiall y el iminated the E-5166-
dependent inhibito ry effect o f the EG F-stil11ulated AA release. 
As shown in Fig 4, H C alo ne at 1 JLM o r E-5 166 alo ne at 100 
JLM sig nifi cantl y inhibited the EG F-stil11ulated AA release . T he 
presence o f H C additi vci y po tentiated the inhib itory effect of E-
5166 on the EGF-stimu lated AA release. H ydrocortisone at 10 
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Figure 1. Eficct of E-5166 on the EG F-stimulated AA release (time course 
s tud y). E piderma l sli ces pretreated w ith or w ithout E-5 166 (100 /LM) fo r 
indica ted periods were prclabclcd w ith 1 '4q AA (0. 1 /LC i/ ml) for 4 h, and 
then incubated with EGF at O. I p.g/ ml fo r 20 min . T he amount of l '4qAA 
released in the medium was de termined and expressed as % of 0 time 
va lue. Each b" ,. represents the standard erro r of 3 sa m ples. 
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Figure 2. Effect of E-5166 on the EGF-stimubted AA release (dose stud y). 
Epidermal sli ces pretreated w ith o r w itho ut E-5166 at va rio us concen-
trations fo r 22 h were prelabekd w ith 1'4QA A (0. 1 p,C i/ ml ) fo r 4 h , and 
then incubated w ith or without EGF at 0. 1 p,g/ ml for 20 min. T he alllo unt 
of 1'4C IA A released in the medium was dete rmined and ex pressed as 
dpill / Ill g prote in :t SEM . Number of sa mples = 3; 01' £'11 circles, control ; 
solid cil'cles, EGF 0. 1 p,g/ml. 
J-L M also inhibited the ECF-stimu lated AA release (55.7 ± 5.5%) 
and the inhibi t ion was enhan ced by E-5 166 trea tm ent to 77.3 ± 
2.0% (n = 3). In o rder to furth er elu cidate the act ion mechanism 
of E-5166, the effect o f phospholipid-breakdown sys tem was 
studi ed. In tota l, in 6 separate experiments the form ati o n of 
[3H] g lycero l- labeled di g lycerol (DC) was stimulated by EC F at 
5 min to 333 ± 49% of th e levels of DC at 0 time. As shown in 
Fi g 5, tran sient in crease of [3Hl g lycero l- labeled ] C fo rmation 
stimul ated by ECF was co mpletely inhibited by pretrea tm ent 
with E-51 66 . In this prelabelin g sys tem w ith 13Hl g lycero l for 1 
h , E- 5166 sli ghtl y inhibited r3H] g lycero l labelin g of DC, w hil e 
[3H] g lycero l labelin g o f PA and PI p lus PS was stimul ated by 
pretreatment w ith E-5 166 (data not shown). 
As shown in Table Ill , the formation of 131--1linosito l-labeled PI 
was also stud ied in a continuous labeling sys tem . E pidermal g rowth 
factor stimu lated the fo rmati on of [3H lin osito l-Iabeled PI, w hile 
pretrea tm ent with E-5 166 inhibited th e ECF-stimulated PI for-
mati on. In this sys tem , E-5166 en han ced th e formation o f 




E·5166 (JOOp M) 





Figure 3. E ffect o f cycloheximide and /o r E-5 166 on the EC F-stilllubted 
AA release. Epiderma l sli ces pretrea ted w ith o r w ithout E-5 166 ( 100 p,M) 
in the presence o r absence of cyclo hex imide (1 p,g/ m l) for 22 h were 
pre labeled w ith 1'4CJAA (0. I p,C i/ ml ) fo r 4 h, and then in cubated w ith 
EG F at 0. 1 p,g/m l for 20 min. T he amoun t of r'''C IA A released in the 
medium was determined and ex pressed as dpm / mg protein /20 min ± 
SEM . Number of sa mples = 3. *: I' < 0.0 1 (compared with NO li e). 
Con tro l, shaded arcas; EGF, Opel/ areas. 
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Figure 4. E ffect of H C and /o r E-5 '166 on the EGF-stimulated AA release. 
Epiderma l sli ces pret rea ted w ith o r w ithout E-5 1()6 (100 p,M) ill the pres-
ence o r absence o f H C ( I p,M) fo r 22 h we re prelabelcd with 1'4C]AA 
(0.1 p,C i/ ml ), and then incubated w ith ECF (0. I p,g/ ml) for 20 111in. The 
amount of l' 4CJAA released ill the medium was determined and expressed 
as dpm/ mg protei n 20 min ± SEM . *a: I' < 0.001 (compared to NO li e). 
** b: I' < 0.01 (co mpared w ith I-lydrocortisOllc o r E-5·166). 
D ISCUSSION 
Like aro11latic retinoids, E-5166 is clinica ll y effe cti ve, no t only 
for hypcrprolifcrative and dyske rato ti c sk in diseases but also for 
inflammato ry skin di seases such as psori as is vu lga ris and pustula r 
pso ri asis . Althou gh it has bcen postulated that the anti-inflam-
m atory act ivity mi ght be du e to an inhibi tion of the production 
of AA-deriv ed m edi ato rs o f infl am m at io n, Ruzicka [12] failed to 
dem o nstrate th e inhibitor y activity o f aromatic retin o id (RoIO-
1670) on cither lipo xygena sc o r cyclooxygcnase activ ities. Fur-
ther , retinoids have becn shown to both in crease l1 3 J and decrease 
14], or not to affect 114] pros taglandin E2 sy nthes is depending 
upon th e type of cells, the retinoid , and its concen tration. E-51 66 
shares a number of bio logic and ph armacolog ic activities w ith 
aro11latic [etin o ids, but it was not clear how E-51 66 works on 
inflammato ry processes . 
We have previous ly reported that ECF stimulated the release 
o f AA thro ug h the activation of PLase A2 o f pi g epidermis [7]. 
T hc generation of free AA from m embrane phospholipids b y 
PLase A2, w hi ch leads to th e fo rm ation of AA m etabolites, is 















0 5 10 0 5 10 
Time (min) 
Figure 5. Effect o f E-5 166 on the EC F-stimulatcd ["H Jg l yce ro l-labeled 
DG fo rmation. Epidermal sli ces pretrea ted with (8) o r witho ut (A) E -
5 166 (100 p,M) for 22 h were prelabeled w ith IJHlg lyce ro l (2 p,C i/ ml) for 
1 h , and then in cubated w ith o r without EC F (0. 1 p,g/ ml ) for 10 min . 
Thc amount of IJHlg lyce ro l-iabcled DC was determ ined and expressed 
as dpm/ mg protein ± SEM fo llowin g thin - layer chro matog raphy analysis 
of li pids ext racted from epidermal hOlll ogenates. Number of sa mples = 
4; "pell circles, contro l; so lid circles, ECF (0. '1 p,g/ ml ). 
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Table III. Effect of E-5166 on the EGF-Stimu lated 
[2H]lnosito l In co rporation into PI 
None 
EGF (0. 1 J.Lg/ llll) 
13H Jlnositol Incorporation 
(dpm/mg protein) 
COlltrol 
1,234 ± 199 
1,76 1 ± 134" 
E-51 66 (100 J.LM) 
1 ,970 ± 303" 
1, ':!65 ± 252" 
Ep ide rmal sli ces prclabclcd w ith or without E-5166 (100 /LM) for 22 h were 
incubated w it h Or w ith o ut EGF (O. I/LS/ml) in the presence of l' H(inos itol ( I/LC i/ ml) 
fo r 1 h. The am o ullt of IJI-Ilinosito l in co rporated in ro PI was derermined and ex-
pressed as dplll / lIl !; protein :!: SEM . Number o f sa mples = 6. 
"p < a.005 (co mpared w ith contro l). 
thought to be a rate-limitin g process . In order to elu cidate the 
mech a nism of ac tion of E-5166 o n the inflammatory processes, 
we s tudied th e effect of E-5166 on the EGF-stil11u latcd AA release 
of pig ep idermis . 
E-5166 significantly inhibited the EGF-stimu lated AA release. 
It required at leas t 6-h in cubation and this inhibitory effect of E-
5166 was parti all y eliminated by the addition of cycloheximide, 
an inhibito r of protein sy nthesis. Furthermore, the presence of 
He a dditively po tentiated the inhibitory effe ct of E-5166 on the 
EGF- stimu lated AA release. 
It has been repo rted that o ne of the important ac tions of co r-
ticosteroids on the inflammatory process is to inhibit PLase A2 
activity by synthetizing an inhibitor protein [15,1 6J. 
As the activation of PLase A2 by EGF was preceded by the 
degradation of PI to DG [10], we were interested in the effect of 
E-5166 on the EGF-stimulated PI turnover. The EGF induced a 
transie nt and sig nifi cant in crease of r3HJ g lycerol-labeled DG for-
ma tion, whi le E -5166 completely inhibited the EGF-stimulated 
DG formation. T he EGF-stimu lated P I form ation was also in-
hibi t e d by E-5166. 
E-5166 failed to inhibit AA re lease stimulated by A23187, which 
activa t es PLase A2 ac tivity witho ut the transient formation of PI 
and P A (17,1 8J. The release of AA by TPA, which activates 
prote in kin ase C directly , w as also inhibited by E-5166, but the 
mech a nism by which TPA stim ul ates AA release is s till unknown. 
These res ults indi cate that E-5166 inhibited the EGF-stimulated 
AA release throug h the inhibition of PI turn over, which is dif-
ferent from the effe ct of HC, although the preci se mechanism of 
action by which E-5166 inhibits PI turnover was not clearly elu-
cidated. 
T h e re are several possible ways in which E-5166 inhibits PI 
turnover stimulated by EGF: (1) E-5166 m ay modulate the EGF 
receptors, (2) E-5166 may inhibit phospholipase C activity, or 
(3) E-5166 m ay inhibit PI resyn thesis. 
In our prelabelin g sys tem, it was observed that E-5166 rather 
inhibited [3HJ g lycerol labeling of DG, while it stimulated 
p H]inositollabeling of PI. In addition , it also stimulated [3HJg lycerol 
labeling of PA and PI plus PS, and [32P] labeling of PA and PI 
pl us PS (data not shown). Sin ce it is reported that retinoids spe-
cifically enhance the number ofEGF recepto rs [19], it is not likely 
tha t E -5166 may modulate them. E-5166 nlay have profound 
effects on phospholipid metabolism of pig epidermis. 
Our prescnt report sugges ts that E-5166 inhibits thc EGF-stim-
ula te d PI brea kdown, the EGF-stimulated AA release, and prob-
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ably the sy nthesis o f AA metabo lites. This inhibitory effect of E-
5166 ma y account for the clinical effectiveness on inflammato ry 
skin di seases . 
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